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ABSTRACT 
      We report a 2-year-old female with a subcutaneous tumor who was initially 
misdiagnosed as suffering from Ewing sarcoma with a positive EWSR1 rearrangement and 
EWS/FLI1 transcript. After finding lymphoblasts in peripheral blood, the diagnosis of acute 
lymphoblastic leukemia was established. This necessitated further analysis of the 
subcutaneous tumor. The tissue was positive for immature B-cell markers and an 
immunoglobulin heavy chain gene rearrangement, which confirmed the final diagnosis of 
common type acute lymphoblastic leukemia with bulk extramedullary disease. The patient 
was treated with chemotherapy and was in remission 30 months after the diagnosis. 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
     The process of diagnosis of small blue round cell tumors (SBRCT) is a difficult task 
from both an oncological and pathological perspective. This group of neoplasms contains a 
considerable number of different tumors, which have similar histological features under light 
microscopy. Therefore, a great help in making this diagnosis and choosing the correct 
treatment has been the introduction of techniques such as immunohistochemistry and 
polymerase chain reaction (PCR) (1-3). Despite the great advances in technology, problems 
still exist with regards to differentiating between similar tumors from that group. This 
difficulty is evident in the differentiation of the Ewing sarcoma family of tumors (ESFT) from 
lymphoblastic lymphoma (LBL) (4,5). 
Here, we report a patient with common type acute lymphoblastic leukemia (ALL), 
bulk extramedullary disease, a chromosome 22 (EWSR1) rearrangement and a positive 
EWS/FLI1 fusion transcript initially presented as a subcutaneous lymphoma masquerading as 
Ewing sarcoma (EWS). 
CASE REPORT 
The patient was a 2-year-old female, who was referred to our surgical department due 
to a subcutaneous mass in the left parietal region. The mass was not painful and her parents 
did not report any other abnormalities. There was no previous significant illnesses in her past 
medical history. The physical examination revealed that she was slightly underweight. There 
was no organomegaly, enlarged lymph nodes, or other abnormalities. The complete blood 
count (CBC) was normal at that time. There was no evidence of leukemic blasts or tumor cells 
in the peripheral blood smear. 
 Within a few days of presentation, the patient underwent a scheduled surgical 
excision of the parietal mass. The initial pathological findings of the resected tissue  showed 
that the tumor consisted of clusters of atypical small cells with hyperchromatic nuclei (Figure 
1a). Immunohistochemistry of the tumor tissue demonstrated a positive reaction to the 
antigens for CD99 (Figure 1b), neuron specific enolase and synaptophysin, but the studies 
were negative for leukocyte common antigen (LCA). Reverse-transcriptase polymerase chain 
reaction (RT-PCR) analysis of the fresh pathological specimen was performed as previously 
described (6). It showed the existence of an EWS/FLI1 type 2 transcript, which is commonly 
associated with ESFT (Figure 1c) (3). A EWSR1 rearrangement from formalin-fixed paraffin-
embedded tumor tissue was subsequently confirmed by fluorescence in situ hybridization 
(FISH) (7). 
 The patient was diagnosed with an extraosseous EWS, and she was transferred to our 
oncology department. Upon admission, another CBC with a differential was performed. This 
showed white blood cells of 12.5×10
9 
/L, a hemoglobin level of 10.3 g/dl and normal platelet 
values of 168×10
9 
/L. Serum levels of lactate dehydrogenase and uric acid were found to be 
within the normal ranges. Malignant blasts (17%) were found in the peripheral blood smear. 
That finding, together with EWS staging requirements, necessitated a bone marrow 
examination. The bone marrow specimen was obtained from the sternum and morphologically 
showed no elements of EWS, but was infiltrated with 65% lymphoblasts  (Figure 2a). These 
were positive for periodic acid-Schiff (PAS) and negative for peroxidase, acid phosphatase, 
and alpha-naphthylacetate esterase (ANAE). Flow cytometric immunophenotyping of the 
bone marrow material was positive for terminal deoxynucleotidyl transferase (TdT), CD10, 
CD19, CD34, cytoplasmic expression of CD79a (cCD79a) and HLA-DR, all of which was 
consistent with the diagnosis of common B cell precursor type ALL. Immunocytochemistry of 
the bone marrow specimen also confirmed CD10 positivity (Figure 2b). Furthermore, RT-
PCR analysis of the bone marrow was performed as previously described (8). The results 
were negative for TEL/AML-1, BCR/ABL, ALL-1/AF-4 transcripts. Polymerase chain 
reaction (PCR) analysis of the bone marrow for immunoglobulin heavy chain gene 
rearrangement (IgH-R) was carried out as described previously and was found to be positive 
(9). However, the bone marrow EWS/FLI1 transcript analysis was not performed by RT-PCR 
at that time due to the scarcity of the specimen; the positive result for the bone marrow 
EWSR1 rearrangement was confirmed by FISH (Figure 2c) (7). 
The original diagnosis was challenged by these results, and further investigations of 
the excised tumor were deemed to be necessary. More detailed immunohistochemistry of the 
subcutaneous mass showed positivity for CD10, CD34, CD79a, CD99, TdT and PAX5. CD20 
antigen, a common marker in B cell lymphomas was negative. We also found a high positivity 
for the Fli1 protein, which is uncommon in lymphomas, although it has been reported (2). 
PCR analysis for IgH-R within the subcutaneous tumor was also positive and showed an 
identical rearrangement to the type that had been found in the analysis of the bone marrow 
(9). The final results indicated that the subcutaneous tumor mass was in fact a bulk 
extramedullary disease as a part of ALL, with a positive EWSR1 rearrangement, expression 
of a EWS/FLI1 fusion transcript and of the FLI1 protein.      
The patient was treated with chemotherapy according to the ALL IC-BFM 2002 
protocol. She went into complete remission on the 33rd day of therapy. Thirty months later 
and after regular follow-up visits to the oncology clinic, the patient shows no signs of her 
previous illness. 
DISCUSSION 
The distinction between ESFT and LBL with extramedullary disease can be difficult 
and a limited panel of antibodies can lead to an erroneous diagnosis. The main problems in 
diagnosis have been the histological features and the presence of the CD99 antigen, which has 
been reported to be positive in both malignancies (1,4). Employing additional tumor-specific 
markers may be helpful, but the most reliable method is detection of the t(11;22)(q24;q12) 
translocation and expression of EWS/FLI1 transcripts (10). Positivity for the FLI1 protein 
could indicate the existence of the fusion gene since FLI1 protein has been shown to have 
increased expression in most cases with the proven presence of the EWS/FLI1 translocation 
(2, 11).  Rare cases have demonstrated that both ESFT and lymphomas can have positivity for 
the CD99 and FLI1 proteins (2). Therefore, the presence of the EWS/FLI1 transcript itself as 
a result of t(11;22)(q24;q12) seems to be important for differential diagnosis. Approximately 
85% of all ESFT cases have been found to be positive for this transcript (12). RT-PCR and 
FISH are the most reliable methods to prove the existence of such a translocation. However, it 
is important to note that a translocation involving the EWSR1 gene detected by the FISH 
method supports a diagnosis of ESFT, but does not prove it. Other solid tumors, such as 
desmoplastic small round cell tumors, clear cell sarcoma, and extraskeletal myxoid 
liposarcoma, may demonstrate the rearrangement of EWSR1 (13).  
The same genetic rearrangement can be present across malignancies of different 
phenotypes. The presence of BCR/ABL in chronic myeloid leukemia (CML) and ALL is the 
most classic example. EWSR1 and ETS (FLI1, ERG) rearrangements associated with ESFT 
have also been described in hematopoietic malignancies (14,15). One case of acute myeloid 
leukemia (AML) with t(11;22)(q24;q12) and a case of granulocytic sarcoma masquerading as 
EWS have been reported (16,17). Also, one case of concomitant EWS and ALL (18), as well 
as the case of EWS as second malignant neoplasm after ALL, have been described (19).  
The present case, which demonstrated both positive EWSR1 gene rearrangement and a 
EWS/FLI1 fusion transcript, suggests that even a confirmation of the EWS/FLI1 transcript 
should not exclude the possibility of a lymphatic origin of the tumor.  It is important to know 
that the identification of genetic rearrangements associated with specific solid tumors, 
leukemias or types of lymphoma, and their use as potential tools in the differential diagnosis 
of these neoplasms, should not be confused with the fact that the diagnosis of any malignancy 
has to be made carefully by integrating all of the diagnostic components. Histopathology, 
immunophenotyping and genetic analysis must all be integrated within the final diagnosis and 
correlated with the clinical data. Therefore, no single marker should be utilized to finalize the 
diagnosis of any malignancy. 
Conflict of Interest Statement 
The authors have no conflicts of interest to declare. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
References 
 
1. Lucas DR, Bentley G, Dan ME, et al. Ewing sarcoma vs. lymphoblastic lymphoma. A 
comparative immunohistochemical study.  Am J Clin Pathol 2001;115:11-17. 
2. Folpe AL, Hill CE, Parham DM, et al. Immunohistochemical detection of FLI-1 protein 
expression: a study of 132 round cell tumors with emphasis on CD99-positive mimics of 
Ewing's sarcoma/primitive neuroectodermal tumor. Am J Surg Pathol 2000;24:1657-1662. 
3. Jambhekar NA, Bagwan IN, Ghule P, et al. Comparative Analysis of Routine Histology, 
Immunohistochemistry, Reverse Transcriptase Polymerase Chain Reaction, and Fluorescence 
In Situ Hybridization in Diagnosis of Ewing Family of Tumors. Arch Pathol Lab Med 
2006;131:1813-1818. 
4. Ozdemirli M, Fanburg-Smith JC, Hartmann DP, et al. Precursor B-Lymphoblastic 
lymphoma presenting as a solitary bone tumor and mimicking Ewing's sarcoma: a report of 
four cases and review of literature. Am J Surg Pathol 1998;22:795-804. 
5. Ozdemirli M, Fanburg-Smith JC, Hartmann DP, et al. Differentiating lymphoblastic 
lymphoma and Ewing's sarcoma: lymphocyte markers and gene rearrangement. Mod Pathol 
2001;14:1175-1182. 
6.Downing JR, Head DR, Parham DM, et al. Detection of the (11;22)(q24;q12) Translocation 
of Ewing’s Sarcoma and Peripheral Neuroectodermal Tumor by Reverse Transcription 
Polymerase Chain Reaction. Am J Pathol 1993;143:1294-1300. 
7. Bridge RS, Rajaram V, Dehner LP, et al. Molecular diagnosis of Ewing sarcoma/primitive 
neuroectodermal tumor in routinely processed tissue: a comparison of two FISH strategies 
and RT-PCR in malignant round cell tumors. Modern Pathology 2006;19:1-8. 
8. Harbott J, Viehmann S, Borkhardt A, et al. Incidence of TEL/AML1 fusion gene analyzed 
consecutively in children with acute lymphoblastic leukemia in relapse. Blood 1997;90:4933-
4937. 
9. van Dongen JJ, Langerak AW, Brüggemann M, et al. Design and standardization of PCR 
primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene 
recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action 
BMH4-CT98-3936. Leukemia 2003;17:2257-2317. 
10. Khoury JD. Ewing sarcoma family of tumors: a model for the new era of integrated 
laboratory diagnostics. Expert Rev Mol Diagn 2008;8:97-105.  
11. Llombart-Bosch A, Navarro S. Immunohistochemical detection of EWS and FLI-1 
proteins in Ewing sarcoma and primitive neuroectodermal tumors. Comparative analysis with 
CD99 (MIC-2) expression. Appl Immunohistochem Mol Morphol 2001;9:255-260. 
12. Riggi N, Stamenkovic I. The biology of Ewing sarcoma. Cancer Lett 2007;254:1-10. 
13.Gulley ML, Kaiser-Rogers KA. A Rational Approach to Genetic Testing for Sarcoma. 
Diagn Mol Pathol 2009;18:1-10. 
14. Martini A, La Starza R, Janssen H, et al. Recurrent Rearrangement of the Ewing’s 
Sarcoma Gene, EWSR1, or Its Homologue, TAF 15, with the Transcription Factor 
CIZ/NMP4 in Acute Leukemia. Cancer Research 2002;62:5408-5412. 
15. Marcucci G, Baldus CD, Ruppert AS, et al. Overexpression of the ETS-Related Gene, 
ERG, Predicts a Worse Outcome in Acute Myeloid Leukemia. J Clin Oncol 2005;23:9234-
9242. 
16. Hawkins JM, Craig JM, Secker-Walker LM, et al. Ewing's sarcoma t(11;22) in a case of 
acute nonlymphocytic leukemia. Cancer Genet Cytogenet 1991;55:157-162.  
17. Haresh KP, Joshi N, Gupta C, et al. Granulocytic sarcoma masquerading as Ewing’s 
sarcoma: A diagnostic dilemma. J Cancer Res Ther 2008;4:137-139. 
18. Masjosthusmann K, Bielack SS, Köhler G, et al. Concomitant Ewing Sarcoma and Acute 
Lymphoblastic Leukemia in a 5-Year-Old Girl. Pediatr Blood Cancer 2005;45:846-849. 
19. Kim GE, Beach B, Gastier Foster JM, et al. Ewing sarcoma as a second malignant 
neoplasm after acute lymphoblastic leukemia. Pediatr Blood Cancer 2005;45:57-59. 
 
 
 
 
 
Figures 
 
Figure 1. Subcutaneous mass arising from the parietal region: (a) tumor tissue is composed of 
clusters of atypical, small blue cells with hyperchromatic nuclei, demonstrated by the 
hematoxylin-eosin stain (H&E)(x40); (b) tumor cells showing positive immunostaining for 
CD99 (Dako Cytomation), using the labeled streptavidin biotin (LSAB) method (x400); and 
(c) reverse-transcriptase polymerase chain reaction (RT-PCR) with the EWS/FLI1 type 2 
transcript (lane 1: DNA Molecular Weight Marker VIII; lane 2: negative control for 
EWS/FLI1 transcript; lane 3: positive control for EWS/FLI1 type 2 transcript; lane 4: 
positive control for EWS/FLI1 type 1 transcript; lane 5: specimen positive for EWS/FLI1 
type 2 transcript). 
 
 
 
 
 
 
Figure 2. Bone marrow specimen (aspirate): (a) lymphoblasts, shown using the May-
Grunwald-Giemsa staining technique (x1000); (b) positive immunocytochemical staining for 
CD10 (Dako Cytomation) (x1000); and (c) results of fluorescent in situ hibridisation (FISH) 
using a locus-specific fluorochrome labeled EWSR1 dual-color break-apart probe showing 
the t(11;22)(q24:q12) translocation in the bone marrow. Fusion of the red and green signal 
pattern is indicative of an intact copy of the EWS gene. A separated signal pattern of green 
(der(11)) and red (der(22)) demonstrates a rearrangement of the EWS gene. 
 
 
